{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T06:11:32Z","timestamp":1654323092102},"reference-count":36,"publisher":"The Japanese Society for Medical Mycology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3314\/mmj.21-00015","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T22:10:40Z","timestamp":1653948640000},"page":"43-47","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Empagliflozin on <i>Candida glabrata<\/i> Adhesion to Vaginal Epithelial Cells"],"prefix":"10.3314","volume":"63","author":[{"given":"Naomi","family":"Sugimoto","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E: Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 126: 121–125, 2006.","DOI":"10.1016\/j.ejogrb.2005.09.015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hirji I, Andersson SW, Guo Z, Hammar N, Gomez-Caminero A: Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 26: 501–505, 2012.","DOI":"10.1016\/j.jdiacomp.2012.06.012"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nyirjesy P, Sobel JD: Genital mycotic infections in patients with diabetes. Postgrad Med 125: 33–46, 2013.","DOI":"10.3810\/pgm.2013.05.2650"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S: Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103: 373–381, 2014.","DOI":"10.1016\/j.diabres.2013.12.052"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Njomnang Soh P, Vidal F, Huyghe E, Gourdy P, Halimi JM, Bouhanick B: Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab 42: 16–24, 2016.","DOI":"10.1016\/j.diabet.2015.07.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Goswami R, Dadhwal V, Tejaswi S, Datta K, Paul A, Haricharan RN, Banerjee U, Kochupillai NP: Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 41: 162–166, 2000.","DOI":"10.1053\/jinf.2000.0723"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) de Leon EM, Jacober SJ, Sobel JD, Foxman B: Prevalence and risk factors for vaginal Candida<\/i> colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2: 1, 2002.","DOI":"10.1186\/1471-2334-2-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nauck MA: Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8: 1335–1380, 2014.","DOI":"10.2147\/DDDT.S50773"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Scheen AJ: SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 14: 1879–1904, 2015.","DOI":"10.1517\/14740338.2015.1100167"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kushner P: Benefits\/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes. Womens Health (Lond) 12: 379–388, 2016.","DOI":"10.2217\/whe-2016-0001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nyirjesy P, Zhao Y, Ways K, Usiskin K: Evaluation of vulvovaginal symptoms and Candida<\/i> colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28: 1173–1178, 2012.","DOI":"10.1185\/03007995.2012.697053"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hostetter MK: Handicaps to host defense: effects of hyperglycemia on C3 and Candida albicans<\/i>. Diabetes 39: 271–275, 1990.","DOI":"10.2337\/diabetes.39.3.271"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hostetter MK, Lorenz JS, Preus L, Kendrick KE: The iC3b receptor on Candida albicans<\/i>: subcellular localization and modulation of receptor expression by glucose. J Infect Dis 161: 761–768, 1990.","DOI":"10.1093\/infdis\/161.4.761"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Gilmore BJ, Retsinas EM, Lorenz JS, Hostetter MK: An iC3b receptor on Candida albicans<\/i>: structure, function, and correlates for pathogenicity. J Infect Dis 157: 38–46, 1988.","DOI":"10.1093\/infdis\/157.1.38"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Gustafson KS, Vercellotti GM, Bendel CM, Hostetter MK: Molecular mimicry in Candida albicans<\/i>. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest 87: 1896–1902, 1991.","DOI":"10.1172\/JCI115214"},{"key":"16","unstructured":"16) Bujdáková H, Paulovičová E, Borecká-Melkusová S, Gašperík J, Kucharíková S, Kolecka A, Lell C, Jensen DB, Würzner R, Chorvát D, Pichová I: Antibody response to the 45 kDa Candida albicans<\/i> antigen in an animal model and potential role of the antigen in adherence. J Med Microbiol 57: 1466–1472, 2008."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Segal E, Soroka A, Schechter A: Correlative relationship between adherence of Candida albicans<\/i> to human vaginal epithelial cells in vitro<\/i> and candidal vaginitis. Sabouraudia 22: 191–200, 1984.","DOI":"10.1080\/00362178485380321"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Elangbam CS, Qualls CW Jr, Dahlgren RR: Cell adhesion molecules—update. Vet Pathol 34: 61–73, 1997.","DOI":"10.1177\/030098589703400113"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Takami S, Yamashita S, Kihara S, Kameda-Takemura K, Matsuzawa Y: High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Atherosclerosis 138: 35–41, 1998.","DOI":"10.1016\/S0021-9150(97)00286-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Drel VR, Obrosova IG, Pacher P: Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 293: H610–H619, 2007.","DOI":"10.1152\/ajpheart.00236.2007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kim SW, Kim CE, Kim MH: Flavonoids inhibit high glucose-induced up-regulation of ICAM-1 via the p38 MAPK pathway in human vein endothelial cells. Biochem Biophys Res Commun 415: 602–607, 2011.","DOI":"10.1016\/j.bbrc.2011.10.115"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Mikamo H, Yamagishi Y, Sugiyama H, Sadakata H, Miyazaki S, Sano T, Tomita T: High glucose-mediated overexpression of ICAM-1 in human vaginal epithelial cells increases adhesion of Candida albicans<\/i>. J Obstet Gynaecol 38: 226–230, 2018.","DOI":"10.1080\/01443615.2017.1343810"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Atabek ME, Akyürek N, Eklioglu BS: Frequency of vaginal Candida<\/i> colonization and relationship between metabolic parameters in children with type 1 diabetes mellitus. J Pediatr Adolesc Gynecol 26: 257–260, 2013.","DOI":"10.1016\/j.jpag.2013.03.016"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sobel JD: Vulvovaginal candidosis. Lancet 369: 1961–1971, 2007.","DOI":"10.1016\/S0140-6736(07)60917-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Bassyouni RH, Wegdan AA, Abdelmoneim A, Said W, AboElnaga F: Phospholipase and aspartyl proteinase activities of Candida<\/i> species causing vulvovaginal candidiasis in patients with type 2 diabetes mellitus. J Microbiol Biotechnol 25: 1734–1741, 2015.","DOI":"10.4014\/jmb.1504.04009"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Sherry L, Kean R, McKloud E, O'Donnell LE, Metcalfe R, Jones BL, Ramage G: Biofilms formed by isolates from recurrent vulvovaginal candidiasis patients are heterogeneous and insensitive to fluconazole. Antimicrob Agents Chemother 61: e01065-17, 2017.","DOI":"10.1128\/AAC.01065-17"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kennedy MA, Sobel JD: Vulvovaginal candidiasis caused by non-albicans Candida<\/i> species: new insights. Curr Infect Dis Rep 12: 465–470, 2010.","DOI":"10.1007\/s11908-010-0137-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, Sreenivas V, Kochupillai N: Prevalence of Candida glabrata<\/i> and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 30: 312–317, 2007.","DOI":"10.2337\/dc06-1469"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T: Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 11: e0166125, 2016.","DOI":"10.1371\/journal.pone.0166125"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Yokoyama H, Nagao A, Watanabe S, Honjo J: Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes. J Diabetes Investig 10: 439–445, 2019.","DOI":"10.1111\/jdi.12912"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Dennerstein GJ, Ellis DH: Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 41: 326–328, 2001.","DOI":"10.1111\/j.1479-828X.2001.tb01238.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ghosh M, Rodriguez-Garcia M, Wira CR: The immune system in menopause: pros and cons of hormone therapy. J Steroid Biochem Mol Biol 142: 171–175, 2014.","DOI":"10.1016\/j.jsbmb.2013.09.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S: Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-Receptor Axis. Horm Metab Res 47: 686–692, 2015.","DOI":"10.1055\/s-0034-1395609"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Yao D, Wang S, Wang M, Lu W: Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway. Mol Med Rep 18: 3625–3630, 2018.","DOI":"10.3892\/mmr.2018.9393"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Bendel CM, St Sauver J, Carlson S, Hostetter MK: Epithelial adhesion in yeast species: correlation with surface expression of the integrin analog. J Infect Dis 171: 1660–1663, 1995.","DOI":"10.1093\/infdis\/171.6.1660"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T, Sesoko S, Woerle HJ, Dugi KA: Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28: 213–219, 2013.","DOI":"10.2133\/dmpk.DMPK-12-RG-082"}],"container-title":["Medical Mycology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/63\/2\/63_21-00015\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T05:43:12Z","timestamp":1654321392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/63\/2\/63_21-00015\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.21-00015","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"21-00015"}}